Next Article in Journal
Role of Fungicides, Application of Nozzle Types, and the Resistance Level of Wheat Varieties in the Control of Fusarium Head Blight and Deoxynivalenol
Next Article in Special Issue
Development of an in Vitro Potency Assay for Anti-anthrax Lethal Toxin Neutralizing Antibodies
Previous Article in Journal
Pharmacological Aspects of Vipera xantina palestinae Venom
Previous Article in Special Issue
Anthrax Lethal Toxin-Mediated Disruption of Endothelial VE-Cadherin Is Attenuated by Inhibition of the Rho-Associated Kinase Pathway
Toxins 2011, 3(11), 1433-1452; doi:10.3390/toxins3111433

Antibodies against Anthrax: Mechanisms of Action and Clinical Applications

1,*  and 1
1 Unité de biotechnologie des anticorps et des toxines, Département de microbiologie, Institut de Recherche Biomédicale des Armées (IRBA-CRSSA), 38702 La Tronche Cedex, France 2 US Army Medical Research and Materiel Command, Fort Detrick, MD 21702, USA
* Author to whom correspondence should be addressed.
Received: 1 September 2011 / Revised: 3 November 2011 / Accepted: 7 November 2011 / Published: 16 November 2011
(This article belongs to the Special Issue Anthrax Toxin)
View Full-Text   |   Download PDF [1088 KB, 25 November 2011; original version 16 November 2011]   |  


B. anthracis is a bioweapon of primary importance and its pathogenicity depends on its lethal and edema toxins, which belong to the A-B model of bacterial toxins, and on its capsule. These toxins are secreted early in the course of the anthrax disease and for this reason antibiotics must be administered early, in addition to other limitations. Antibodies (Abs) may however neutralize those toxins and target this capsule to improve anthrax treatment, and many Abs have been developed in that perspective. These Abs act at various steps of the cell intoxication and their mechanisms of action are detailed in the present review, presented in correlation with structural and functional data. The potential for clinical application is discussed for Abs targeting each step of entry, with four of these molecules already advancing to clinical trials. Paradoxically, certain Abs may also enhance the lethal toxin activity and this aspect will also be presented. The unique paradigm of Abs neutralizing anthrax toxins thus exemplifies how they may act to neutralize A-B toxins and, more generally, be active against infectious diseases.
Keywords: anthrax toxins; protective antigen; lethal factor; edema factor; antibodies anthrax toxins; protective antigen; lethal factor; edema factor; antibodies
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Froude II, J.W.; Thullier, P.; Pelat, T. Antibodies against Anthrax: Mechanisms of Action and Clinical Applications. Toxins 2011, 3, 1433-1452.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert